|
Thursday, September 5, 2024 |
|
Eisai Accelerates Progress in Oncology Research with New Data at ESMO Congress 2024 |
Eisai Co., Ltd. announced today the presentation of research across various types of cancer from its oncology portfolio and pipeline during the European Society for Medical Oncology (ESMO) Congress 2024, which is taking place virtually and in-person in Barcelona, Spain from September 13 to 17. more info >> |
|
Monday, September 2, 2024 |
|
Eisai Announces Status Relating to Acquisition of Own Shares |
Eisai Co., Ltd. announced today that it has acquired its own shares based on Article 40 of its Articles of Incorporation pursuant to the provisions of Article 459, paragraph 1 of the Companies Act. more info >> |
|
Thursday, August 22, 2024 |
|
Leqembi (lecanemab) Authorized for Early Alzheimer's Disease in Great Britain |
Eisai Co., Ltd. and Biogen Inc.announced today that the humanized amyloid-beta(Abeta) monoclonal antibody "Leqembi" (brand name, generic name: lecanemab) has been granted a Marketing Authorization by the Medicines and Healthcare products Regulatory Agency (MHRA) in Great Britain. more info >> |
|
Wednesday, August 14, 2024 |
|
"LEQEMBI" (Lecanemab) Approved for the Treatment of Alzheimer's Disease in the United Arab Emirates |
Eisai Co., Ltd. and Biogen Inc. announced today that the Ministry of Health and Prevention in the United Arab Emirates (UAE) has approved humanized anti-soluble aggregated amyloid-beta (Abeta;) monoclonal antibody "LEQEMBI" (lecanemab) for the treatment of Alzheimer's disease (AD). more info >> |
|
Tuesday, August 6, 2024 |
|
Eisai: Update Regarding the Regulatory Status of LEQEMBI Subcutaneous Formulation |
Eisai Co., Ltd. reconfirmed that the regulatory status for anti-amyloid beta (Aβ) protofibril antibody LEQEMBI (generic name:lecanemab) subcutaneous (SC) autoinjector, explained at the Financial Disclosure Meeting on August 2, 2024, is as follows. more info >> |
|
Wednesday, July 31, 2024 |
|
New Clinical Data Demonstrates Three Years of Continuous Treatment with Dual-Acting LEQEMBI (lecanemab-irmb) Continues to Significantly Benefit Early Alzheimer's Disease Patients Presented at AAIC 2024 |
Eisai Co., Ltd. and Biogen Inc. announced today that the latest findings for lecanemab-irmb (U.S. brand name: LEQEMBI), an anti-amyloid beta (Abeta) protofibril* antibody for the treatment of early Alzheimer's disease (AD), were presented at the Alzheimer's Association International Conference (AAIC) 2024, held in Philadelphia, and virtually. more info >> |
|
Monday, July 29, 2024 |
|
Update on Regulatory Review of Lecanemab for Early Alzheimer's Disease in the European Union |
Eisai Co., Ltd. and Biogen Inc. announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a negative opinion on the Marketing Authorization Approval (MAA) for the humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody lecanemab as treatment for early AD (mild cognitive impairment due to Alzheimer?s disease (AD) and mild AD). more info >> |
|
Thursday, July 25, 2024 |
|
Eisai and EcoNaviSta Enter into Business Alliance Agreement Aimed at Building a Dementia Ecosystem and Commence Collaboration |
Eisai Co., Ltd. and EcoNaviSta Inc. announced today that they have entered into a business alliance agreement and commenced collaboration with the aim of building an ecosystem in the area of dementia, which is a pressing matter in Japan's super-aging society. more info >> |
|
Tuesday, July 23, 2024 |
|
Eisai to Present Dual-Acting Lecanemab Three-Year Efficacy and Safety Data and Discuss Long-Term Outcomes of Continued Treatment at the Alzheimer's Association International Conference 2024 |
The conference will be held in Philadelphia and virtually from July 28 to August 1, 2024. Eisai will present data and research in four (4) oral and 15 poster presentations at the meeting and will host two (2) sessions on lecanemab. more info >> |
|
Tuesday, July 16, 2024 |
|
エーザイ、ホスラブコナゾールのアジア・オセアニアにおけるライセンス契約を佐藤製薬と締結 |
エーザイ株式会社(本社:東京都、代表執行役 CEO:内藤晴夫)は、このたび、抗真菌剤ホスラブコナゾールについて、真菌性疾患に対するアジア・オセアニアにおける開発および商業化に関するライセンス契約を佐藤製薬株式会社(本社:東京都、以下 佐藤製薬)と締結したことをお知らせします。 more info >> |
|
|
|